Latest News

The FDA granted approval of the combination of teclistamab and daratumumab for patients with 1-3 prior lines of therapy in myeloma.

Sagar Lonial, MD, discusses the significance of the MRD end point for the ongoing priority review of iberdomide in multiple myeloma.

The FDA has granted a priority review and accepted the NDA for rusfertide in PV.

In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma could shed light on clinical outcomes.

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

Modeling shows zanubrutinib may cut progression and costs versus acalabrutinib in relapsed/refractory CLL, especially in high-risk patients.

Adding nivolumab/ipilimumab to liver-directed melphalan improved outcomes in patients with metastatic uveal melanoma.

Efficacy and safety results from the phase 1 PAnTHA study presented at 2026 ASCO GU.

Induction ipilimumab/nivolumab plus chemoradiotherapy consolidation was associated with bladder preservation in muscle-invasive urothelial carcinoma.

FDA clears real-time AI OCT to spot breast cancer margins during lumpectomy, helping surgeons reduce repeat operations and improve outcomes.

Clinical validation results show changes in methylated circulating tumor DNA (ctDNA) measured prior to treatment initiation and before cycle 3 of therapy were strongly associated with objective response and clinical benefit.

AKY-1189 gains fast track designation in urothelial cancer.

CAPItello-281 shows capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

IMvigor011 shows post-cystectomy ctDNA timing and levels predict relapse, while adjuvant atezolizumab clears ctDNA and extends survival in MIBC.

FDA grants tentative approval to PNT2003, a Lutathera radioequivalent PRRT for SSTR+ GEP-NETs, paving way for wider access by 2026.

Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her colleagues’ research into IGF-1 and GLP-1 signaling pathways in liposarcoma.

New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.

Experts explain how MRI trends, seizures, and spectroscopy guide when IDH-mutant glioma monitoring ends and radiation or chemo begins.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

FDA oncology updates in February 2026 deliver new approvals, oral and monthly dosing options, and key NDA reviews, easing treatment burden across hard-to-treat cancers.

The LITESPARK-024 trial showed a manageable safety profile for belzutifan and palbociclib in advanced RCC, but the response rate did not exceed that of historical single-agent belzutifan.

ASCO GU 2026 previews and FDA rulings spotlight new targeted options in bladder, lung, breast, and colorectal cancers.

Findings from the phase 3 LITESPARK-011 trial favored belzutifan/lenvatinib vs cabozantinib in PFS and ORR.

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines.

An integrated analysis of the RETAIN-1 and RETAIN-2 trials demonstrates that circulating tumor DNA is a powerful prognostic indicator for metastatic recurrence in muscle-invasive bladder cancer.

Phase 2 results showed efficacy and tolerability of disitamab vedotin in pretreated HER2+ and HER2-low urothelial cancer.

In certain patients with prostate cancer, darolutamide enhanced PSMA expression, according to the Daro-PET study.

Neoadjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival and overall survival compared with gemcitabine plus cisplatin.

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for FDA approvals in multiple myeloma.